Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification Bum Jun KimYoo Jin KimDae Young Zang PRECLINICAL STUDIES 02 May 2020 Pages: 1633 - 1640
The near-infrared fluorescent dye IR-780 was coupled with cabazitaxel for castration-resistant prostate cancer imaging and therapy Yu ZhengGuangdong HouJianlin Yuan PRECLINICAL STUDIES 02 May 2020 Pages: 1641 - 1652
CPBMF65, a synthetic human uridine phosphorylase-1 inhibitor, reduces HepG2 cell proliferation through cell cycle arrest and senescence Elisa Feller Gonçalves da SilvaKelly Goulart LimaJarbas Rodrigues de Oliveira PRECLINICAL STUDIES 04 May 2020 Pages: 1653 - 1663
The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells Małgorzata Opydo-ChanekIwona CichońLidia Mazur PRECLINICAL STUDIES Open access 04 May 2020 Pages: 1664 - 1676
Mechanisms of Efficacy of the FGFR1–3 Inhibitor AZD4547 in Pediatric Solid Tumor Models Nikki PhanhthilathSara HakimPeter E. Zage PRECLINICAL STUDIES 20 May 2020 Pages: 1677 - 1686
ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib Sho SakamotoKazuhiro SatoKatsutoshi Nakayama PRECLINICAL STUDIES 20 May 2020 Pages: 1687 - 1695
Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells Seung-Woo HongJae-Sik ShinTae Won Kim PRECLINICAL STUDIES 27 May 2020 Pages: 1696 - 1706
Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance Hao ChenXiaoling ZhuRenfang Mao PRECLINICAL STUDIES 28 May 2020 Pages: 1707 - 1716
Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics Ying ZhangFrancesca GarofanoIngo G. H. Schmidt-Wolf PRECLINICAL STUDIES Open access 04 June 2020 Pages: 1717 - 1729
The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma Guihong LiuYachun LuMing Chen PRECLINICAL STUDIES 12 June 2020 Pages: 1730 - 1742
Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo Tao SongMingyu ZhangZhijie Dai PRECLINICAL STUDIES 07 August 2020 Pages: 1743 - 1754
A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors Mojun ZhuJulian R. MolinaAlex A. Adjei PHASE I STUDIES 24 April 2020 Pages: 1755 - 1762
Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors Jaffer A. AjaniMilind JavleKenzo Iizuka PHASE I STUDIES Open access 06 May 2020 Pages: 1763 - 1773
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment Jean-Pierre DelordGuillem ArgilésLillian L. Siu PHASE I STUDIES 14 May 2020 Pages: 1774 - 1783
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma David A. ReardonAnnick DesjardinsAndrew B. Lassman PHASE I STUDIES 20 May 2020 Pages: 1784 - 1795
Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation Philippe B. PierrillasEmilie HeninMichel Tod PHASE I STUDIES 25 May 2020 Pages: 1796 - 1806
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma Bradley A. McGregorMichael GordonToni K. Choueiri PHASE I STUDIES 29 May 2020 Pages: 1807 - 1814
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors Charlotte LemechNatasha WoodwardJasgit Sachdev PHASE I STUDIES 10 June 2020 Pages: 1815 - 1825
First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects Meng-na WangYun KuangGuo-ping Yang PHASE I STUDIES Open access 13 June 2020 Pages: 1826 - 1835
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer Shunsuke KondoMasaomi TajimiToshihiko Doi PHASE I STUDIES Open access 23 June 2020 Pages: 1836 - 1845
Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer Shunsuke KondoMasaomi TajimiToshihiko Doi Correction 07 September 2020 Pages: 1846 - 1846
Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study Ling LiFei KongMingzhi Zhang PHASE II STUDIES Open access 03 May 2020 Pages: 1847 - 1853
Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial Kazuhisa NakashimaYuichi OzawaHaruyasu Murakami PHASE II STUDIES 18 May 2020 Pages: 1854 - 1861
A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic/apyrimidinic endonuclease 1 Yuxiao WangXuemei LiDong Wang PHASE II STUDIES Open access 11 June 2020 Pages: 1862 - 1871
Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer Tatyana V. GorodnovaAnna P. SokolenkoEvgeny N. Imyanitov Phase II Studies 26 June 2020 Pages: 1872 - 1878
Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trial Bastien CabarrouCarlos Gomez-RocaThomas Filleron Review 07 May 2020 Pages: 1879 - 1887
The old CEACAMs find their new role in tumor immunotherapy Zi-Wen HanZhi-Wu LyvHong-Wu Xin Review 02 June 2020 Pages: 1888 - 1898
Correction to: The old CEACAMs find their new role in tumor immunotherapy Zi-Wen HanZhi-Wu LyvHong-Wu Xin Correction 22 June 2020 Pages: 1899 - 1900
Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review Koichi OgawaHiroyasu KanedaTomoya Kawaguchi Short Report 12 May 2020 Pages: 1901 - 1905
Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer Satoshi IgawaTaihei OnoKatsuhiko Naoki Short Report 15 May 2020 Pages: 1906 - 1914
Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study Shingo NasuHidekazu SuzukiTomonori Hirashima Short Report 15 June 2020 Pages: 1915 - 1920